|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Torre LA, Siegel RL and Jemal A: Lung
cancer statistics. Adv Exp Med Biol. 893:1–19. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pao W and Chmielecki J: Rational,
biologically based treatment of EGFR-mutant non-small-cell lung
cancer. Nat Rev Cancer. 10:760–774. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nan X, Xie C, Yu X and Liu J: EGFR TKI as
first-line treatment for patients with advanced EGFR
mutation-positive non-small-cell lung cancer. Oncotarget.
8:75712–75726. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gazdar AF: Activating and resistance
mutations of EGFR in non-small-cell lung cancer: Role in clinical
response to EGFR tyrosine kinase inhibitors. Oncogene. 28 (Suppl
1):S24–S31. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lee CC, Shiao HY, Wang WC and Hsieh HP:
Small-molecule EGFR tyrosine kinase inhibitors for the treatment of
cancer. Expert Opin Investig Drugs. 23:1333–1348. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yu HA, Arcila ME, Rekhtman N, Sima CS,
Zakowski MF, Pao W, Kris MG, Miller VA, Ladanyi M and Riely GJ:
Analysis of tumor specimens at the time of acquired resistance to
EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.
Clin Cancer Res. 19:2240–2247. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Su KY, Chen HY, Li KC, Kuo ML, Yang JC,
Chan WK, Ho BC, Chang GC, Shih JY, Yu SL, et al: Pretreatment
epidermal growth factor receptor (EGFR) T790M mutation predicts
shorter EGFR tyrosine kinase inhibitor response duration in
patients with non-small-cell lung cancer. J Clin Oncol. 30:433–440.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cross DA, Ashton SE, Ghiorghiu S, Eberlein
C, Nebhan CA, Spitzler PJ, Orme JP, Finlay MR, Ward RA, Mellor MJ,
et al: AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated
resistance to EGFR inhibitors in lung cancer. Cancer Discov.
4:1046–1061. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Soejima K, Yasuda H and Hirano T:
Osimertinib for EGFR T790M mutation-positive non-small cell lung
cancer. Expert Rev Clin Phar. 10:31–38. 2017. View Article : Google Scholar
|
|
11
|
Thress KS, Paweletz CP, Felip E, Cho BC,
Stetson D, Dougherty B, Lai Z, Markovets A, Vivancos A, Kuang Y, et
al: Acquired EGFR C797S mutation mediates resistance to AZD9291 in
non-small cell lung cancer harboring EGFR T790M. Nat Med.
21:560–562. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ricordel C, Friboulet L, Facchinetti F and
Soria JC: Molecular mechanisms of acquired resistance to
third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer. Ann
Oncol. 29 (Suppl 1):i28–i37. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shi P, Oh Y-T, Deng L, Zhang G, Qian G,
Zhang S, Ren H, Wu G, Legendre B Jr, Anderson E, et al: Overcoming
acquired resistance to AZD9291, a third-generation EGFR inhibitor,
through modulation of MEK/ERK-dependent Bim and Mcl-1 degradation.
Clin Cancer Res. 23:6567–6579. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zou M, Xia S, Zhuang L, Han N, Chu Q, Chao
T, Peng P, Chen Y, Gui Q and Yu S: Knockdown of the Bcl-2 gene
increases sensitivity to EGFR tyrosine kinase inhibitors in the
H1975 lung cancer cell line harboring T790M mutation. Int J Oncol.
42:2094–2102. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nakajima W, Sharma K, Hicks MA, Le N,
Brown R, Krystal GW and Harada H: Combination with vorinostat
overcomes ABT-263 (navitoclax) resistance of small cell lung
cancer. Cancer Biol Ther. 17:27–35. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Emi M, Kim R, Tanabe K, Uchida Y and Toge
T: Targeted therapy against Bcl-2-related proteins in breast cancer
cells. Breast Cancer Res. 7:R940–R952. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Beale PJ, Rogers P, Boxall F, Sharp SY and
Kelland LR: BCL-2 family protein expression and platinum drug
resistance in ovarian carcinoma. Br J Cancer. 82:436–440. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mu P, Nagahara S, Makita N, Tarumi Y,
Kadomatsu K and Takei Y: Systemic delivery of siRNA specific to
tumor mediated by atelocollagen: Combined therapy using siRNA
targeting Bcl-xL and cisplatin against prostate cancer. Int J
Cancer. 125:2978–2990. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Quadros MR, Connelly S, Kari C, Abrams MT,
Wickstrom E and Rodeck U: EGFR-dependent downregulation of Bim in
epithelial cells requires MAPK and PKC-delta activities. Cancer
Biol Ther. 5:498–504. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chou TC: Drug combination studies and
their synergy quantification using the Chou-Talalay method. Cancer
Res. 70:440–446. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sukrithan V, Deng L, Barbaro A and Cheng
H: Emerging drugs for EGFR-mutated non-small cell lung cancer.
Expert Opin Emerg Drugs. 24:5–16. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wu SG and Shih JY: Management of acquired
resistance to EGFR TKI-targeted therapy in advanced non-small cell
lung cancer. Mol Cancer. 17:382018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Santarpia M, Liguori A, Karachaliou N,
Gonzalez-Cao M, Daffinà MG, D'Aveni A, Marabello G, Altavilla G and
Rosell R: Osimertinib in the treatment of non-small-cell lung
cancer: Design, development and place in therapy. Lung Cancer
(Auckl). 8:109–125. 2017.PubMed/NCBI
|
|
24
|
Bollinger MK, Agnew AS and Mascara GP:
Osimertinib: A third-generation tyrosine kinase inhibitor for
treatment of epidermal growth factor receptor-mutated non-small
cell lung cancer with the acquired Thr790Met mutation. J Oncol
Pharm Pract. 24:379–388. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lazzari C, Gregorc V, Karachaliou N,
Rosell R and Santarpia M: Mechanisms of resistance to osimertinib.
J Thorac Dis. 12:2851–2858. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kitada S, Pedersen IM, Schimmer AD and
Reed JC: Dysregulation of apoptosis genes in hematopoietic
malignancies. Oncogene. 21:3459–3474. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yamaguchi R, Lartigue L and Perkins G:
Targeting Mcl-1 and other Bcl-2 family member proteins in cancer
therapy. Pharmacol Ther. 195:13–20. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Faber AC, Farago AF, Costa C, Dastur A,
Gomez-Caraballo M, Robbins R, Wagner BL, Rideout WM III, Jakubik
CT, Ham J, et al: Assessment of ABT-263 activity across a cancer
cell line collection leads to a potent combination therapy for
small-cell lung cancer. Proc Natl Acad Sci USA. 112:E1288–E1296.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sarosiek KA, Ni Chonghaile T and Letai A:
Mitochondria: Gatekeepers of response to chemotherapy. Trends Cell
Biol. 23:612–619. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lu M, Liu B, Xiong H, Wu F, Hu C and Liu
P: Trans-3,5,4-trimethoxystilbene reduced gefitinib resistance in
NSCLCs via suppressing MAPK/Akt/Bcl-2 pathway by upregulation of
miR-345 and miR-498. J Cell Mol Med. 23:2431–2441. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tse C, Shoemaker AR, Adickes J, Anderson
MG, Chen J, Jin S, Johnson EF, Marsh KC, Mitten MJ, Nimmer P, et
al: ABT-263: A potent and orally bioavailable Bcl-2 family
inhibitor. Cancer Res. 68:3421–3428. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Saelens X, Festjens N, Vande Walle L, van
Gurp M, van Loo G and Vandenabeele P: Toxic proteins released from
mitochondria in cell death. Oncogene. 23:2861–2874. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sarosiek KA, Chi X, Bachman JA, Sims JJ,
Montero J, Patel L, Flanagan A, Andrews DW, Sorger P and Letai A:
BID preferentially activates BAK while BIM preferentially activates
BAX, affecting chemotherapy response. Mol Cell. 51:751–765. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Shukla S, Saxena S, Singh BK and Kakkar P:
BH3-only protein BIM: An emerging target in chemotherapy. Eur J
Cell Biol. 96:728–738. 2017. View Article : Google Scholar : PubMed/NCBI
|
